Dr. Rachna Shroff, a renowned cancer researcher who was diagnosed with her own aggressive form of the disease, has died. She ...

Dr. Rachna Shroff, a pioneer in gastrointestinal cancer research, has died at age 47 of the same disease for which she was ...

Dr. Rachna Shroff, a University of Arizona oncologist and internationally recognized expert in bile duct and other ...

A systematic review of 27 guideline families using AGREE II and AGREE-REX finds that clinical practice guidelines for ...

Nice to meet you. I run the "Anticancer Drug Encyclopedia."I am a practicing pharmacist and hold certifications and ...

Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin ...

Nice to meet you. I run the "Anticancer Drug Encyclopedia." I am a practicing pharmacist and hold certifications and specialized qualifications in the field of oncology. In my daily work, I have heard ...

Ivonescimab plus gemcitabine/cisplatin achieved statistically significant overall survival improvement versus durvalumab plus the same chemotherapy in first-line advanced biliary tract cancer.

Dublin, March 30, 2026 (GLOBE NEWSWIRE)-- The "Bile Duct Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The bile duct cancer market is witnessing robust growth, ...

Dr Rachna Shroff was internationally recognised for her work on cholangiocarcinoma, commonly known as bile duct cancer.